FDA committee approves loosening peptide regulation despite own evidence - bioxconomy.com

Stay Updated Stay Updated Partnering Related Topics Licensing M&A Growth Strategy Recent in Partnering See All Partnering$1.8bn merger unites Supernus and Indivior in CNS therapeutics play$1.8bn merger unites Supernus and Indivior in CNS th

Stay Updated Stay Updated Partnering

Related Topics Nucleic Acids

Antibodies and Peptides

Advanced Therapies Recent in Modalities See All ModalitiesFDA committee approves loosening peptide regulation despite own evidenceFDA committee approves loosening peptide regulation despite own evidencebyMillie Hoe Aug 4, 20264 Min Read ModalitiesDose of Discovery: Erik Sontheimer on the evolution of genome editingDose of Discovery: Erik Sontheimer on the evolution of genome editingbySøren Hough,Ayokunmi Ajetunmobi Jul 29, 2026 Business Strategy

Related Topics Compliance, Regulatory and Legal

Access and Channel

Finance and Accounting

Clinical Trials

Pricing and Contracting Recent in Business Strategy See All Clinical TrialsNeurologic trial failures linked to inadequate measurement tools, study saysNeurologic trial failures linked to inadequate measurement tools, study saysbyGareth Macdonald Aug 4, 20262 Min Read Clinical TrialsBlockchain smart contracts could secure trial data and restore trustBlockchain smart contracts could secure trial data and restore trustbyGareth Macdonald Aug 3, 20262 Min Read Modalities

Antibodies and Peptides

News

FDA committee approves loosening peptide regulation despite own evidence An FDA advisory committee recently approved relaxing restrictions on “gray market” peptides.

Millie Hoe,Reporter,BioProcess InsiderAugust 4, 2026 4 Min Read BioXconomy/Millie Hoe Last week, the US Food and Drug Administration FDA held a two-day advisory committee meeting concerning popular “gray market” peptides.

The committee was looking at removing seven compounds from the FDA’s category two CAT2 designation, which identifies drugs that may pose significant safety risks.

The peptides would be moved to the bulk 503A category substance list, allowing state licensed physicians and pharmacists to compound and prescribe the drug products.

The makeup of the advisory committee has recently sparked backlash, with several members having ties to the peptide industry.

Gray market peptides are part of the ever-growing DIY injectables trend that arose out of the success of GLP-1s and their analogs.

While officially prescribed GLP-1s are backed by clinical trials and the World Health Organization, the ambiguous peptide compounds touted by the US Health and Human Services HHS secretary Robert F.

Kennedy, Jr.

have been deemed not fit for human consumption.

Related:DIY dosing: Experimental injectable peptides craze takes US by storm Despite this, various online sources have regarded several popular compounds as a panacea, claiming to heal everything from torn tendons to autoimmune diseases.

Of the seven gray market peptides evaluated, six were voted onto the 503A bulk substances list by a majority.

Several of these compounds have been anecdotally linked to serious side effects, such as gastrointestinal issues, anaphylaxis, and increased risk of pancreatic inflammation.

The decision comes contrary to FDA expert recommendations to disallow all seven compounds included in the nomination based on current scientific evidence.

The majority of the evidence presented by the FDA cited concerns over compounds being poorly characterized, a lack of safety information, high risks of immunogenicity and contamination, and insufficient clinical data.

Six out of the 14 panelists are medical doctors associated with private clinics offering peptide treatments.

All six panel members associated with peptide therapies voted to either pass or abstained from voting for all compounds proposed.

This included Haleem Mohammed, chief medical officer of Gameday Men’s Health; Asare Christian of Aether Medicine; Joshua Starbuck of Makena Health; Kris Wusterhausen of Resurge clinic; Gabriel Alizaidy, scientific director at Maximus; and Melissa Loseke of the Re-New Institute.

“The demand does not vanish when we vote no,” Mohammed said in his final remarks to the committee.

“I want to close with what we actually did today.

We didn’t approve a drug.

Nobody put a finished product on the shelf.

Our patients want peptides.” Related:Canada unveils generic Wegovy alternative, challenging Novo “I support a licensed pharmacy under a state board and a valid prescription from a licensed physician.

I support medications tested for potency, sterility, and screened for the impurities that actually cause harm.” During its introductory remarks on July 23, the FDA clarified that any drug placed on the 503A bulk list “is not FDA approved, is not required to have a label to inform patients and providers how to use it, and is not required to comply with current good manufacturing practice.” The FDA continued to explain that, although drugs must be made in sanitary conditions, neither suppliers nor prescribers are required to report adverse events.

Some committee members stated reservations in their closing remarks.

“I’m not convinced by the strength of the preclinical evidence and of the efficacy and safety,” said Constantino Iadecola, professor of neuroscience at Cornell University and director of the Brain and Mind Research Institute.

“We can’t skip the rigorous scientific studies that are needed when we endorse any kind of product,” added neurologist and national program director for pain management in the Veterans Health Administration Friedhelm Sandbrink.

“ This could lead patients away from other evidence-based therapies.” Related:GLP-1 killer?

Oligo therapy hits obesity at its source Committee member, patient advocate, and president of the NorCal CarciNET community Josh Mailman added that “we have to make sure that we have the safety data before we turn it loose on patients.” “ The FDA will consider the Pharmacy Compounding Advisory Committee's recommendations, consult with the United States Pharmacopeia, and use these considerations to develop a proposed rule,” a spokesperson for the US Department of Health and Human Services told BioXconomy.

“After the proposed rule is published, the public will have an opportunity to submit comments to the docket.

The FDA will consider those comments before issuing a final rule amending the 503A Bulks List.” “The final rule may include all, some, or none of the substances proposed for inclusion on the 503A Bulks List.” Quotes have been lightly edited for clarity.

TIDES Europe Nov 3, 2026 TO Nov 5, 2026 |Amsterdam, Netherlands Europe's largest and most comprehensive oligonucleotide and peptide therapeutics event featuring scientific breakthroughs, manufacturing innovations, and regulatory insights.

Access new data & case studies from world-renowned speakers and companies across the entire landscape of oligos, peptides, mRNA, drug delivery and partnering strategies.

RegisterLearn More RegisterLearn More About the Author Millie Hoe Reporter, BioProcess Insider Millie Hoe is a life sciences reporter for BioProcess Insider and BioXconomy, covering biomanufacturing, modalities and partnering and investment.

She has a strong scientific background in biomedical sciences and healthcare, recently completing her Master's of Science MSc earlier this year.

See more from Millie Hoe Explore further Modalities

Dose of Discovery: Erik Sontheimer on the evolution of genome editing

Jul 29, 2026 Modalities

Forge Bio partners with Restore Vision to advance AAV therapies for retinal disorders

Jul 29, 2026 From Partnering and Investment insights to Scientific developments to Commercialization strategies, sign up to receive free to your mailbox

Latest See all Partnering

$1.8bn merger unites Supernus and Indivior in CNS therapeutics play

$1.8bn merger unites Supernus and Indivior in CNS therapeutics play See BioXconomy first on Google Top Stories

Peptides referenced: Semaglutide, GLP-1.